Literature DB >> 29881788

Advances in bacterial cancer therapies using synthetic biology.

Tiffany Chien1, Anjali Doshi1, Tal Danino1,2,3.   

Abstract

Synthetic biology aims to apply engineering principles to biology by modulating the behavior of living organisms. An emerging application of this field is the engineering of bacteria as a cancer therapy by the programming of therapeutic, safety, and specificity features through genetic modification. Here, we review progress in this engineering including the targeting of bacteria to tumors, specific sensing and response to tumor microenvironments, remote induction methods, and controllable release of therapeutics. We discuss the most prominent bacteria strains used and their specific properties and the types of therapeutics tested thus far. Finally, we note current challenges, such as genetic stability, that researchers must address for successful clinical implementation of this novel therapy in humans.

Entities:  

Year:  2017        PMID: 29881788      PMCID: PMC5986102          DOI: 10.1016/j.coisb.2017.05.009

Source DB:  PubMed          Journal:  Curr Opin Syst Biol        ISSN: 2452-3100


  92 in total

1.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

Authors:  C Clairmont; K C Lee; J Pike; M Ittensohn; K B Low; J Pawelek; D Bermudes; S M Brecher; D Margitich; J Turnier; Z Li; X Luo; I King; L M Zheng
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

2.  A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly.

Authors:  Gaia Sciaranghella; Samir K Lakhashe; Mila Ayash-Rashkovsky; Saied Mirshahidi; Nagadenahalli B Siddappa; Francis J Novembre; Vijayakumar Velu; Rama Rao Amara; Chenghui Zhou; Sufen Li; Zhongxia Li; Fred R Frankel; Ruth M Ruprecht
Journal:  Vaccine       Date:  2010-11-09       Impact factor: 3.641

3.  A synthetic genetic edge detection program.

Authors:  Jeffrey J Tabor; Howard M Salis; Zachary Booth Simpson; Aaron A Chevalier; Anselm Levskaya; Edward M Marcotte; Christopher A Voigt; Andrew D Ellington
Journal:  Cell       Date:  2009-06-26       Impact factor: 41.582

4.  Programmable bacteria detect and record an environmental signal in the mammalian gut.

Authors:  Jonathan W Kotula; S Jordan Kerns; Lev A Shaket; Layla Siraj; James J Collins; Jeffrey C Way; Pamela A Silver
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

5.  Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors.

Authors:  R M Ryan; J Green; P J Williams; S Tazzyman; S Hunt; J H Harmey; S C Kehoe; C E Lewis
Journal:  Gene Ther       Date:  2009-01-29       Impact factor: 5.250

6.  Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth.

Authors:  Markus Loeffler; Gaelle Le'Negrate; Maryla Krajewska; John C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-24       Impact factor: 11.205

7.  A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy.

Authors:  Jan Peter van Pijkeren; David Morrissey; Ian R Monk; Michelle Cronin; Simon Rajendran; Gerald C O'Sullivan; Cormac G M Gahan; Mark Tangney
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

8.  RNA-guided editing of bacterial genomes using CRISPR-Cas systems.

Authors:  Wenyan Jiang; David Bikard; David Cox; Feng Zhang; Luciano A Marraffini
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

9.  Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo.

Authors:  John T Heap; Jan Theys; Muhammad Ehsaan; Aleksandra M Kubiak; Ludwig Dubois; Kim Paesmans; Lieve Van Mellaert; Richard Knox; Sarah A Kuehne; Phillipe Lambin; Nigel P Minton
Journal:  Oncotarget       Date:  2014-04-15

Review 10.  Current development in genetic engineering strategies of Bacillus species.

Authors:  Huina Dong; Dawei Zhang
Journal:  Microb Cell Fact       Date:  2014-05-03       Impact factor: 5.328

View more
  19 in total

1.  Engineering bacteria for cancer therapy.

Authors:  Tetsuhiro Harimoto; Tal Danino
Journal:  Emerg Top Life Sci       Date:  2019-11-11

2.  Rapid screening of engineered microbial therapies in a 3D multicellular model.

Authors:  Tetsuhiro Harimoto; Zakary S Singer; Oscar S Velazquez; Joanna Zhang; Samuel Castro; Taylor E Hinchliffe; William Mather; Tal Danino
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-17       Impact factor: 11.205

3.  Shining light on molecular communication.

Authors:  Bhuvana Krishnaswamy; Megan N McClean
Journal:  ACM Int Conf Nanoscale Comput Commun (2020)       Date:  2020-10-07

Review 4.  A rapid screening platform to coculture bacteria within tumor spheroids.

Authors:  Tetsuhiro Harimoto; Dhruba Deb; Tal Danino
Journal:  Nat Protoc       Date:  2022-07-29       Impact factor: 17.021

5.  Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice.

Authors:  Hanlin Zhang; Meng Dong; Shouli Yuan; Wanzhu Jin
Journal:  Biotechnol Lett       Date:  2022-08-25       Impact factor: 2.716

6.  Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria.

Authors:  Yale Yue; Jiaqi Xu; Yao Li; Keman Cheng; Qingqing Feng; Xiaotu Ma; Nana Ma; Tianjiao Zhang; Xinwei Wang; Xiao Zhao; Guangjun Nie
Journal:  Nat Biomed Eng       Date:  2022-05-02       Impact factor: 29.234

7.  Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy.

Authors:  Che-Wei Hu; You-Chiun Chang; Cheng-Hao Liu; Yao-An Yu; Kurt Yun Mou
Journal:  Mol Ther       Date:  2022-04-18       Impact factor: 12.910

8.  Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities.

Authors:  Kenneth Timmis; James Kenneth Timmis; Harald Brüssow; Luis Ángel Fernández
Journal:  Microb Biotechnol       Date:  2019-01       Impact factor: 5.813

Review 9.  Targeting Programmed Fusobacterium nucleatum Fap2 for Colorectal Cancer Therapy.

Authors:  Kumar Ganesan; Songhe Guo; Sundaz Fayyaz; Ge Zhang; Baojun Xu
Journal:  Cancers (Basel)       Date:  2019-10-18       Impact factor: 6.639

Review 10.  Bacteria-cancer interactions: bacteria-based cancer therapy.

Authors:  Mai Thi-Quynh Duong; Yeshan Qin; Sung-Hwan You; Jung-Joon Min
Journal:  Exp Mol Med       Date:  2019-12-11       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.